Tango Therapeutics, Inc.

NASDAQ:TNGX

3.1 (USD) • At close December 20, 2024
Bedrijfsnaam Tango Therapeutics, Inc.
Symbool TNGX
Munteenheid USD
Prijs 3.1
Beurswaarde 332,995,800
Dividendpercentage 0%
52-weken bereik 2.7 - 13.005
Industrie Biotechnology
Sector Healthcare
CEO Dr. Barbara L. Weber M.D.
Website https://www.tangotx.com

An error occurred while fetching data.

Over Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease

Vergelijkbare Aandelen

Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

AURA

8.2 USD

Geron Corporation logo

Geron Corporation

GERN

3.49 USD

Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc.

STOK

11.68 USD

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.98 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.1 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.8 USD

GH Research PLC logo

GH Research PLC

GHRS

6.85 USD

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

53.35 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)